Prostate cancer, version 1.2014.

Publication Type:

Journal Article

Source:

Journal of the National Comprehensive Cancer Network : JNCCN, Volume 11, Issue 12, p.1471-9 (2013)

Keywords:

2013, Clinical Research Division, January 2014

Abstract:

The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.